CA Patent

CA2495864C — Aripiprazole complex formulation and method

Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2011-09-27 · 15y expired

What this patent protects

An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a b-cyclodextrin, preferably, sulfobutyl ether b-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mi…

USPTO Abstract

An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a b-cyclodextrin, preferably, sulfobutyl ether b-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA2495864C
Jurisdiction
CA
Classification
—
Expires
2011-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.